Status:
UNKNOWN
Matrix Metalloproteinases Expression in the Neointimal Hyperplasia Induced by Drug Eluting Stent (DES) Implantation
Lead Sponsor:
Dankook University
Conditions:
Coronary Artery Disease
Stent Restenosis
Eligibility:
All Genders
20-90 years
Phase:
NA
Brief Summary
If intimal growth is such that the initial lumen is narrowed significantly, distal blood flow is restricted and chronic tissue ischemia results. This occurs in native coronary arteries and during rest...
Detailed Description
Materials and methods Subjects (patients) Patients derived from a population of patients referred to 12 months follow-up coronary angiography for ischemic heart disease who are enable to be performed ...
Eligibility Criteria
Inclusion
- Ischemic heart disease
Exclusion
- Left main coronary artery disease (defined as a stenosis of \> 50%)
- Prior complex lesion morphologies (aorto-ostial, bifurcation with \>2.0 mm side branch, severe calcification, chronic total occlusion)
- Long lesion that require more than two stents
- Inflammatory conditions likely to be associated with an acute phase response, autoimmune and neoplastic disease
- Advanced liver disease, renal failure, and valvular heart disease
- If there was persistent cardiogenic shock, refractory pulmonary edema, or hemodynamic instability (blood pressure \<90/50 mmHg).
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2019
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03375528
Start Date
January 1 2018
End Date
May 1 2019
Last Update
December 18 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.